Reading this on a mobile device? Try our optimized mobile version here:

March 12, 2013
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • Report: 907 biotech vaccines and therapies in the pipeline
    Biopharmaceutical companies are developing 907 biologic vaccines and drugs for more than 100 conditions, according to a Pharmaceutical Research and Manufacturers of America report. The lineup includes 134 vaccines for infectious diseases, 338 drugs for cancer, 71 for autoimmune diseases and 58 for cardiovascular diseases. Drug Store News (3/11) LinkedInFacebookTwitterEmail this Story
Companies Look to Capture Part of Growing Respiratory Market
While another storm hit the East Coast of the U.S. served to delay the scheduled FDA Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting last week, South San Francisco-based Theravance Inc. and its partner GlaxoSmithKline plc, of London, shouldn't have too much longer to wait for what is predicted to be a positive review from the PADAC for their once-daily inhaled corticosteroid. Find out the details.

  Health Care & Policy 
  • FDA shakes up drug marketing units to achieve multiple goals
    The FDA's Office of Prescription Drug Promotion is restructuring its professional and consumer marketing review divisions to provide tight supervision of direct-to-consumer advertising. The changes, which include organizing oversight by therapeutic class instead of target audience, will help achieve the goals of removing redundancy, enhancing work distribution and increasing efficiency, Center for Drug Evaluation and Research Director Dr. Janet Woodcock wrote in an e-mail. (3/8) LinkedInFacebookTwitterEmail this Story
  • Bayer, J&J launch two more late-stage trials of rivaroxaban
    Bayer and Johnson & Johnson are beginning two more late-stage trials of the blood thinner Xarelto, or rivaroxaban, after failing to get the FDA's OK for the treatment of patients with acute coronary syndrome. One trial involves patients with chronic heart failure and significant coronary artery disease. The other will involve patients with nonvalvular atrial fibrillation. PharmaTimes (U.K.) (3/11) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  • Active Biotech gets $42.6M boost from Swedish investor
    Active Biotech raised $42.6 million by issuing 6 million shares to Swedish firm Investor AB. The company will use the money to support development of its partnered and proprietary programs including tasquinimod for prostate cancer and other solid cancers, and laquinimod for multiple sclerosis. BioWorld (free content) (3/8) LinkedInFacebookTwitterEmail this Story
  Global Developments 
  Food & Agriculture 
  Industrial & Environmental 
  • Algenol reports higher yield in algae-to-ethanol process
    Algenol Biofuels' algae-to-ethanol facility in Lee County, Fla., has achieved continuous output at 9,000 gallons per acre per year, above the firm's original target of 6,000. "I fully expect our talented scientific team to achieve sustained production rates above 10,000 by the end of this year," chief executive Paul Woods said. (3/11) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

We are all worms. But I do believe that I am a glow-worm."
--Winston Churchill,
British prime minister

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information